If you are wondering which share will be best for investment in recent times then you should have an idea about Suven Pharma Share Price Target. Today in this article we will explain the basic idea about the Suven Pharma Share Price Target 2025, 2027, and 2030. Based on our research and expert advice, this blog is about the company’s growth, performance, etc.
In this article, we will describe the company’s financial growth, the business policy of the company, the shareholding pattern of the company, and the forecast share price yearly. Suven Pharma Share Price Target is a trading share in the share market. We use expert research and analysis to understand the Suven Pharma Share Price Target. This article may be useful to those who want to invest in this share. Let’s explore the Suven Pharma Share Price Target 2025 to 2030.
Read More: IRFC Share Price Target 2025 to 2050
Introduction
Suven Pharmaceuticals Limited, a pharmaceutical company was established On November 6, 2018, and was incorporated under the Companies Act. Suven Pharmaceuticals Ltd. is a medicine development and manufacturing company with over 33 years of experience.
Overview
The Headquarters of Suven Pharma Ltd Company is located in Hyderabad. The business established branches around the USA and India. Suven Pharmaceutical Ltd is a corporation that possesses top-notch manufacturing facilities for producing fine chemical intermediates and pharmaceuticals for other pharmaceutical companies. Suven Pharmaceuticals Ltd. is involved in Cohansa Lifesciences’ merger process.
Suven Pharmaceutical Ltd. employs approximately a thousand people, including over four hundred scientists for research. Suven Pharmaceutical Ltd Company was selected as a production partner by more than 25 major international companies. Additionally, the company produces nanotech items (ointment creams, suspensions), semi-solids (oils, creams, gels), and sachets (wet non-woven cloth, powers).
| Company Name | Suven Pharmaceutical Company |
| Market Cap | ₹22,500 Crore |
| Book Value | ₹81 |
| Face Value | ₹1.1 |
| DIV. YIELD | 01% |
| 52 Week High | ₹895 |
| 52 Week Low | ₹471 |
| P/B Ratio | 8.19 |
| NSE Sine | SUVENPHAR |
| Products | Solid Orals, Pellets, Semisolids, Injectable Complex Drugs, Tablets, Capsules, and Topical Cloth Products. |
Financial Data analysis
To understand the company’s performance, we need to consider its PE ratio, return on assets, current ratio, and return on equity. The following section will discuss these parameters. The target share price for Suven Pharma is also influenced by these ratios.
| PE Ratio | Return on assets( ROA) | Current ratio | Return on equity(ROE) |
| 70.2 | 14% | 3.7% | 28% |
Suven Pharma Share Price Target 2024
Suven Pharma was a pharmaceutical company that was significant to the pharmaceutical industry. By providing medications at the time, the company saved the lives of numerous people. Suven Pharma is a prominent player in the Indian pharmaceutical industry. A close examination of the pharmaceutical business reveals that the corporation has a robust range of products.
| Year | Suven Pharma Share Price Target 2024 |
| 1st Price Target | 725 |
| 2nd Price Target | 1025 |
Suven Pharma Share Price Target 2025
The primary operations of the company involve the production of Active Pharmaceutical Ingredients (APIs) and New Chemical Entity Intermediates (NCEIs). Additionally, Suven Pharmaceutical Ltd. The company has agreements to supply research chemicals to over 25 chemical and pharmaceutical industries. For this reason, the Suven Pharma Company’s R&D team uses cutting-edge technology to create novel, difficult goods.
| Year | Suven Pharma Share Price Target 2024 |
| 1st Price Target | 1055 |
| 2nd Price Target | 1255 |
Suven Pharma Share Price Target 2027
Because Suven Pharma exports its goods outside of India, the products’ FII investment increased to 11–12.5%. Research from the most recent fiscal year 2022–2023 indicates that the company’s total FDI (Foreign Direct Investment) during the previous five years was ₹42,578. Suven Pharma shipped advanced medication intermediates and active pharmaceutical components, both of which were examined by a dedicated team before export.
| Year | Suven Pharma Share Price Target 2024 |
| 1st Price Target | 1655 |
| 2nd Price Target | 1823 |
Suven Pharma Share Price Target 2030
The company’s good cash conversation cycle of 51.3 days indicates that it can allocate funds for manufacturing efficiently. With a PE of 46 and a robust ROE of 26%, the company continues to have excellent financial support.
The company’s net profit for the March 2022 fiscal year was ₹569 crore, up from ₹308 crore in the same month the previous year. This indicates that the company consistently maintains a profit margin. The company’s sales have increased by 17.% during the past three years, while its profit has grown by 17%.
| Year | Suven Pharma Share Price Target 2030 |
| 1st Price Target | 2,515 |
| 2nd Price Target | 2,955 |
Suven Pharma Share Price Target 2040
By 2040, if Suven Pharma sustains its average growth rate over the past decade, the stock could reach ₹4670 Should this forecast come true, it would mark a 180.53% rise from its current value.
| Year | Suven Pharma Share Price Target 2040 |
| 1st Price Target | 4670 |
| 2nd Price Target | 4730 |
Suven Pharma Share Price Target 2050
According to projections, the Suven Pharma share price target for 2050 is set at ₹7060, assuming the company maintains the same average annual growth rate observed over the past decade. For the Year 2050, it means you we want to know about its performance in future.
| Year | Suven Pharma Share Price Target 2050 |
| 1st Price Target | 6825 |
| 2nd Price Target | 7060 |
Advantages and Disadvantages Of Suven Pharma
Every share offers various benefits as well as drawbacks. Thus, the following list of benefits and drawbacks equally applies to the Suven Pharma Share Price Target.
Advantages
- The company is growing while having little debt, which is extremely encouraging for future expansion.
- The business has kept an effective operating margin of 46% during the past five years.
- The company has a strong 60% promoter holding capacity, which is advantageous for its expansion.
- FII institution is expanding its shareholding capacity, which is encouraging for the expansion of the business.
Disadvantages
- falling revenue growth and profit growth during the last three quarters.
- Cash flow generation is insufficient to support the company’s expansion.
- With a high rate of 32.5%, the EBITDA
You Can Read: IDBI Bank Share Price Target 2025
FAQs
Who is the CEO of Suven Pharma?
At Suven Pharma Company, the CEO is Dr. Sudhir Kumar Singh.
What is the MRPL share price target for 2024?
The first price target is ₹725, while the second price target is ₹1025, according to the Suven Pharma share price estimate for 2024.
What is the MRPL share price target for 2025?
The first price goal is ₹1055 and the second price target is ₹1255 if we look at the projected share price target Suven Pharma Share Price goal 2025.
What is the MRPL share price target for 2027?
The first price target is ₹1,655, and the second price target is ₹1,823, if we look at the projected share price objective for 2027.
What is the MRPL share price target for 2030?
Suven Pharma’s share price target for 2030 is expected to be ₹2,955 at the first price target and ₹2,515 at the second price target.
Conclusion
We hope https://pricepredictionhub.com/ will provide you with some fundamental knowledge on the Suven Pharma Share Price Target. We make sure that, over time, the Suven Pharma Share Price Target may rise to an extremely high position by conducting the necessary research and consulting with specialists. Suven Pharma is mostly associated with the field of medicine. Thus, as the need for this industry grows, so does the share’s potential for future profit.
You are welcome to share this website if you believe it will be useful to you. Please use the comment box to ask any questions you may have, and we will do our best to address them and find a solution. We appreciate you coming to our website and staying with us.
Disclaimer
This prediction is for informational purposes only and should not be considered financial advice. Share price forecasts are Hypothetical and subject to change based on market conditions and other factors. Always conduct your research and consult with a financial advisor before making investment decisions. Past performance does not always guarantee future results.